Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market

26% Annual IO Growth Forecast Alluring

 
• By Brian Yang
  
CSTONE SIGNS ON PFIZER TO COMMERCIALIZE ITS PD-L1 TO CAPTURE CHINA GROWTH • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia